NR 666.510(3)(3) Additional standards for reverse distributors managing evaluated hazardous waste pharmaceuticals. A reverse distributor that does not have a license or interim status shall comply with all of the following conditions, in addition to the requirements of sub. (1), for the management of evaluated hazardous waste pharmaceuticals: NR 666.510(3)(a)(a) Accumulation area at the reverse distributor. A reverse distributor shall designate an on-site accumulation area where it will accumulate evaluated hazardous waste pharmaceuticals. NR 666.510(3)(b)(b) Inspections of on-site accumulation area. A reverse distributor shall inspect its on-site accumulation area at least once every 7 calendar days, looking at containers for leaks and for deterioration caused by corrosion or other factors, as well as for signs of diversion. NR 666.510(3)(c)(c) Personnel training at a reverse distributor. Personnel at a reverse distributor who handle evaluated hazardous waste pharmaceuticals are subject to the training requirements under s. NR 662.017 (1) (g). NR 666.510(3)(d)(d) Labeling and management of containers at on-site accumulation areas. A reverse distributor accumulating evaluated hazardous waste pharmaceuticals in containers in an on-site accumulation area shall do all of the following: NR 666.510(3)(d)1.1. Label the containers with the words, “hazardous waste pharmaceuticals.” NR 666.510(3)(d)2.2. Ensure the containers are in good condition and managed to prevent leaks. NR 666.510(3)(d)3.3. Use containers that are made of or lined with materials that will not react with, and are otherwise compatible with, the evaluated hazardous waste pharmaceuticals, so that the ability of the container to contain the waste is not impaired. NR 666.510(3)(d)4.4. Keep containers closed, if the container is holding liquid or gel evaluated hazardous waste pharmaceuticals. If the liquid or gel evaluated hazardous waste pharmaceuticals are in their original, intact, sealed packaging or repackaged in intact, sealed packaging, they are considered to meet the closed container standard. NR 666.510(3)(d)5.5. Manage any container of ignitable or reactive evaluated hazardous waste pharmaceuticals, or any container of commingled incompatible evaluated hazardous waste pharmaceuticals so that the container does not have the potential to do any of the following: NR 666.510(3)(d)5.b.b. Produce uncontrolled toxic mists, fumes, dusts, or gases in sufficient quantities to threaten human health. NR 666.510(3)(d)5.c.c. Produce uncontrolled flammable fumes or gases in sufficient quantities to pose a risk of fire or explosions. NR 666.510(3)(d)5.d.d. Damage the structural integrity of the container of hazardous waste pharmaceuticals. NR 666.510(3)(d)6.6. Accumulate evaluated hazardous waste pharmaceuticals that are prohibited from being combusted because of the dilution prohibition under s. NR 668.03 (3), for example arsenic trioxide (P012), in separate containers from other evaluated hazardous waste pharmaceuticals at the reverse distributor. NR 666.510(3)(e)(e) Hazardous waste numbers. Prior to shipping evaluated hazardous waste pharmaceuticals off-site, all containers shall be marked with the applicable hazardous waste numbers, or hazardous waste codes. A nationally recognized electronic system, such as bar coding or radio frequency identification, may be used to identify the EPA hazardous waste numbers. NR 666.510(3)(f)(f) Shipments. A reverse distributor shall ship evaluated hazardous waste pharmaceuticals that are destined for a permitted or interim status treatment, storage, or disposal facility in accordance with the applicable shipping standards specified in s. NR 666.508 (1) or (2). NR 666.510(3)(g)(g) Procedures for a reverse distributor for managing rejected shipments. A reverse distributor that sends a shipment of evaluated hazardous waste pharmaceuticals to a designated facility with the understanding that the designated facility can accept and manage the waste, and later receives that shipment back as a rejected load in accordance with the manifest discrepancy provisions under s. NR 664.0072 or 665.0072, may accumulate the returned evaluated hazardous waste pharmaceuticals on-site for up to an additional 90 calendar days in the on-site accumulation area provided the rejected or returned shipment is managed in accordance with sub. (1) and this subsection. Upon receipt of the returned shipment, the reverse distributor shall do all of the following: NR 666.510(3)(g)1.a.a. Item 18c of the original manifest, if the original manifest was used for the returned shipment. NR 666.510(3)(g)1.b.b. Item 20 of the new manifest, if a new manifest was used for the returned shipment. NR 666.510(3)(g)3.3. Within 30 calendar days of receipt of the rejected shipment of the evaluated hazardous waste pharmaceuticals, send a copy of the manifest to the designated facility that returned the shipment to the reverse distributor. NR 666.510(3)(g)4.4. Within 90 calendar days of receipt of the rejected shipment, transport or offer for transport the returned shipment of evaluated hazardous waste pharmaceuticals in accordance with the applicable shipping standards under s. NR 666.508 (1) or (2). NR 666.510(3)(h)(h) Land disposal restrictions. Evaluated hazardous waste pharmaceuticals are subject to the land disposal restrictions under ch. NR 668. A reverse distributor that accepts potentially creditable hazardous waste pharmaceuticals from off-site shall comply with the land disposal restrictions in accordance with s. NR 668.07 (1) requirements. NR 666.510(3)(i)(i) Reporting by a reverse distributor for evaluated hazardous waste pharmaceuticals. NR 666.510(3)(i)1.1. ‘Annual reporting by a reverse distributor.’ A reverse distributor that ships evaluated hazardous waste pharmaceuticals off-site shall prepare and submit a single copy of an annual report to the department by March 1 of each year in accordance with s. NR 662.041. NR 666.510(3)(i)2.2. ‘Exception reporting by a reverse distributor for a missing copy of the manifest - shipments from a reverse distributor to a designated facility.’